Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Sep, 2017 | Pages:
67 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) - Pipeline Review, H2 2017 Summary According to the recently published report 'Placenta Growth Factor - Pipeline Review, H2 2017'; Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) pipeline Target constitutes close to 11 molecules. Out of which approximately 11 molecules are developed by Companies. Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) - Placental growth factor is a protein encoded by the PGF gene. Placental growth factor (PGF) is a member of the VEGF (vascular endothelial growth factor). It plays an important role in angiogenesis and endothelial cell growth, stimulating their proliferation and migration. It binds to the receptor FLT1/VEGFR-1. PGF is also expressed in many other tissues, including the villous trophoblast. The report 'Placenta Growth Factor - Pipeline Review, H2 2017' outlays comprehensive information on the Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities. It also reviews key players involved in Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Phase II, Preclinical and Discovery stages are 2, 3, 3 and 3 respectively. Report covers products from therapy areas Ophthalmology, Metabolic Disorders and Oncology which include indications Diabetic Macular Edema, Wet (Neovascular / Exudative) Macular Degeneration, Branch Retinal Vein Occlusion, Central Retinal Vein Occlusion, Choroidal Neovascularization, Diabetic Retinopathy, Macular Edema, Medulloblastoma, Myopia, Neovascular Glaucoma, Non-Proliferative Diabetic Retinopathy (NPDR), Optic Neuropathy, Rectal Cancer, Retinal Vein Occlusion and Retinopathy. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape for Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) - The report reviews Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) targeted therapeutics and enlists all their major and minor projects - The report assesses Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news and deals related to Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) targeted therapeutics Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand the targeted therapy areas and indications for Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) - Identify the use of drugs for target identification and drug repurposing - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) development landscape - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) - Overview 6 Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) - Therapeutics Development 7 Products under Development by Stage of Development 7 Products under Development by Therapy Area 8 Products under Development by Indication 9 Products under Development by Companies 10 Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) - Therapeutics Assessment 13 Assessment by Mechanism of Action 13 Assessment by Route of Administration 14 Assessment by Molecule Type 16 Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) - Companies Involved in Therapeutics Development 18 Alteogen Inc 18 Chengdu Kanghong Pharmaceuticals Group Co Ltd 18 Formycon AG 18 Lupin Ltd 19 Regeneron Pharmaceuticals Inc 20 ThromboGenics NV 20 Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) - Drug Profiles 22 (aflibercept + nesvacumab) - Drug Profile 22 Product Description 22 Mechanism Of Action 22 R&D Progress 22 aflibercept - Drug Profile 24 Product Description 24 Mechanism Of Action 24 R&D Progress 24 aflibercept biosimilar - Drug Profile 36 Product Description 36 Mechanism Of Action 36 R&D Progress 36 aflibercept biosimilar - Drug Profile 37 Product Description 37 Mechanism Of Action 37 R&D Progress 37 aflibercept biosimilar - Drug Profile 38 Product Description 38 Mechanism Of Action 38 R&D Progress 38 aflibercept SR - Drug Profile 39 Product Description 39 Mechanism Of Action 39 R&D Progress 39 conbercept - Drug Profile 40 Product Description 40 Mechanism Of Action 40 R&D Progress 40 SL-186 - Drug Profile 42 Product Description 42 Mechanism Of Action 42 R&D Progress 42 SL-188 - Drug Profile 43 Product Description 43 Mechanism Of Action 43 R&D Progress 43 THR-317 - Drug Profile 44 Product Description 44 Mechanism Of Action 44 R&D Progress 44 ziv-aflibercept - Drug Profile 47 Product Description 47 Mechanism Of Action 47 R&D Progress 47 Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) - Dormant Products 52 Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) - Discontinued Products 53 Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) - Product Development Milestones 54 Featured News & Press Releases 54 Aug 30, 2017: Bayer to showcase latest Ophthalmology research at EURETINA 2017 54 May 24, 2017: ThromboGenics to present THR-317 Pre-clinical Research Findings at the European Association for the Study of Diabetes, Eye Complications Study Group Meeting in Budapest, Hungary 55 May 09, 2017: The first UK trial comparing intravitreal aflibercept and laser for proliferative diabetic retinopathy reports at ARVO 2017 56 Jan 17, 2017: ONCURIOUS Announces European Commission Confirmed Orphan Medicinal Product Designation for TB-403 for Medulloblastoma 57 Jan 10, 2017: ThromboGenics Enrolls First Patients in Phase II Clinical Study Evaluating THR-317 (Anti-PlGF) for Diabetic Macular Edema 58 Sep 28, 2016: Patients with BRVO, a sight threatening eye condition, now have first-line access to EYLEA (aflibercept solution for injection) on the NHS 58 Jun 08, 2016: NICE draft recommendation on the use of aflibercept (EYLEA) for management of branch retinal vein occlusion goes against Royal College of Ophthalmologists' guidance 59 May 25, 2016: Regeneron Announces Important US Prescribing Information Clarification for EYLEA (aflibercept) Injection 60 May 02, 2016: Oncurious NV, BioInvent and NMTRC Initiating Phase I/IIa Study with TB-403 for the Treatment of Medulloblastoma 61 Mar 15, 2016: BioInvent and Oncurious Partner with US Research Consortium to Accelerate Phase I/IIa Trial of TB-403 62 Mar 01, 2016: Aflibercept in myopic choroidal neovascularization: Added benefit not proven 62 Feb 29, 2016: Formycon discloses details on second pipeline product - FYB203 is a biosimilar for Eylea (aflibercept) 63 Jan 07, 2016: BioInvent announces FDA acceptance of the Investigational New Drug application for the phase I/IIa study with TB-403 64 Oct 30, 2015: Bayer Receives EU Approval for EYLEA for the Treatment of Visual Impairment Secondary to Myopic Choroidal Neovascularization 64 Sep 25, 2015: Bayer's Eye Drug Recommended for EU Approval in Fifth Indication 65 Appendix 66 Methodology 66 Coverage 66 Secondary Research 66 Primary Research 66 Expert Panel Validation 66 Contact Us 66 Disclaimer 67
List of Tables
Number of Products under Development by Stage of Development, H2 2017 7 Number of Products under Development by Therapy Areas, H2 2017 8 Number of Products under Development by Indication, H2 2017 9 Number of Products under Development by Companies, H2 2017 10 Products under Development by Companies, H2 2017 11 Products under Development by Companies, H2 2017 (Contd..1), H2 2017 12 Number of Products by Stage and Mechanism of Actions, H2 2017 13 Number of Products by Stage and Route of Administration, H2 2017 15 Number of Products by Stage and Molecule Type, H2 2017 17 Pipeline by Alteogen Inc, H2 2017 18 Pipeline by Chengdu Kanghong Pharmaceuticals Group Co Ltd, H2 2017 18 Pipeline by Formycon AG, H2 2017 19 Pipeline by Lupin Ltd, H2 2017 19 Pipeline by Regeneron Pharmaceuticals Inc, H2 2017 20 Pipeline by ThromboGenics NV, H2 2017 21 Dormant Projects, H2 2017 52 Discontinued Products, H2 2017 53
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
